2 very small studies with hospitalized patients in Taiwan.
RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p
=0.4. Risk of PCR+ at day 14, RR 0.76, p
This paper also reports on a small retrospective study with 12 of 28 HCQ patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p
Chen et al., 7/10/2020, Randomized Controlled Trial, Taiwan, Asia, peer-reviewed, 19 authors.
risk of no virological cure, 24.0% lower, RR 0.76, p = 0.71, treatment 4 of 21 (19.0%), control 3 of 12 (25.0%), day 14.
median time to PCR-, 50.0% lower, relative time 0.50, p = 0.40, treatment 21, control 12.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of